Based on the numbers below, I conclude that cash burn is about 11M$/quarter. Extra pale - you are right, the operating loss number includes the 11M$ goodwill depriciation, which is a non cash expense.
GENZYME BIOSURGERY (A Division of Genzyme Corporation)
Combined Statements of Operations
(Unaudited,amounts in thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2001 2000 2001 2000
Total revenues $63,219 $34,607 $177,739 $105,812
Operating costs and
expenses:
Cost of products sold 27,128 18,539 87,897 51,170
Cost of services sold 3,148 2,903 9,096 8,949
Selling, general and
administrative 27,827 23,288 93,816 68,095
Research and
development 12,352 8,935 35,027 26
Amortization of
intangibles 11,729 1,426 35,042 4,279
Total operating
costs and expenses 82,184 55,091 260,878 158,723
Operating loss (18,965) (20,484) (83,139) (52,911)
Other income
(expenses):
Equity in net loss of
unconsolidated
affiliate - - (1,316) -
Other 35 33 80 75
Investment income 431 1,274 1,370 4,873
Interest expense (3,026) (347) (11,455) (973)
Total other income
(expenses) (2,560) 960 (11,321) 3,975
Division net loss (21,525) (19,524) (94,460) (48,936)
Tax benefit allocation 2,444 - 11,434 -
Net loss attributable
to stocks allocated to
Genzyme Biosurgery $(19,081) $(19,524) $(83,026) $(48,936) |
